Triple-negative breast cancer (TNBC) represents a formidable challenge in oncology, distinguished by its aggressive biological profile and the absence of specific molecular targets commonly exploited by precision therapies. Unlike other breast cancer subtypes, TNBC cells are devoid of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2), rendering them unresponsive to widely successful hormone therapies and HER2-targeted drugs. This lack of conventional targets necessitates reliance on chemotherapy, which, while often effective initially, frequently leads to drug resistance and disease recurrence. The virulent nature of TNBC, characterized by rapid proliferation, early metastatic dissemination, and a higher propensity for relapse compared to other breast cancers, underscores the urgent need for innovative therapeutic strategies.
In a significant advancement published in Breast Cancer Research, a team of scientists at the Medical University of South Carolina (MUSC) Hollings Cancer Center has unveiled an experimental antibody that offers a multi-pronged attack against TNBC. This pioneering research suggests a potential new pathway to not only curb tumor growth and metastatic spread but also to re-educate the immune system and circumvent the notorious problem of chemotherapy resistance. The preclinical findings indicate that this novel antibody can attenuate the expansion of primary tumors, significantly reduce the development of pulmonary metastases, restore the functionality of immune cells typically suppressed by cancer, and eradicate cancer cells that have become unresponsive to standard chemotherapeutic agents.
Central to this promising therapeutic approach is the targeted inhibition of a protein known as secreted frizzled-related protein 2 (SFRP2). This biomolecule plays a pivotal, multifaceted role in fostering the progression and survival of cancerous cells. SFRP2 is implicated in stimulating angiogenesis, the formation of new blood vessels crucial for tumor nourishment and growth. Furthermore, it confers resistance to programmed cell death (apoptosis) in cancer cells, allowing them to evade natural cellular demise. Critically, SFRP2 also contributes to the immunosuppressive microenvironment surrounding tumors, weakening the very immune cells that would otherwise be tasked with eliminating the malignancy.
The identification of SFRP2 as a key oncogenic facilitator is the culmination of nearly two decades of dedicated research spearheaded by Dr. Nancy Klauber-DeMore, a distinguished breast surgical oncologist and co-leader of the Developmental Cancer Therapeutics Research Program at Hollings. Her laboratory first pinpointed SFRP2’s involvement in breast cancer in 2008. Since then, the research trajectory has meticulously uncovered the intricate mechanisms by which SFRP2 drives breast cancer proliferation, enhances its metastatic potential, and contributes to immune system exhaustion within the tumor microenvironment. This extensive foundational work laid the groundwork for the subsequent development of an antibody specifically designed to neutralize SFRP2’s detrimental effects. The project exemplified a collaborative spirit, drawing expertise from multiple departments at MUSC, including Surgery, Biochemistry and Molecular Biology, and Pathology and Laboratory Medicine.
The experimental therapeutic is a humanized monoclonal antibody, engineered with exquisite precision to selectively bind to SFRP2. This targeted attachment is crucial, as it allows the antibody to block SFRP2’s cancer-promoting activities without indiscriminately affecting healthy cells. The specificity of monoclonal antibodies represents a significant advantage over conventional chemotherapy, which often damages healthy tissues alongside cancerous ones, leading to debilitating side effects. The development team, which included MUSC surgical residents Dr. Lillian Hsu and former resident Dr. Julie Siegel, meticulously crafted this antibody to ensure its efficacy and safety profile in preclinical models.
A groundbreaking discovery arising from this study concerns SFRP2’s presence not only within the cancer cells themselves but also in the surrounding immune cells, including tumor-infiltrating lymphocytes and macrophages. This finding, termed a "paradigm shift" by Dr. Klauber-DeMore, offers an entirely novel perspective on understanding and potentially manipulating the immune microenvironment. Macrophages, a type of white blood cell, are particularly significant in cancer immunity and typically exist in two primary states: M1 and M2. M1 macrophages are pro-inflammatory and play a crucial role in activating the immune system to combat cancer, while M2 macrophages adopt an immunosuppressive role, promoting tumor growth and tissue repair. In the context of TNBC, macrophages often skew towards the M2, tumor-supportive phenotype, contributing to the cancer’s ability to evade immune surveillance.
Remarkably, treatment with the SFRP2 antibody was observed to induce a significant shift in macrophage polarization. Following antibody administration, macrophages began to release substantial quantities of interferon-gamma, a potent immune signaling molecule. This release effectively reprogrammed the macrophages, driving them from the pro-tumorigenic M2 state back towards the anti-tumor M1 phenotype. Even in animal models afflicted with advanced disease and established metastases, the antibody successfully rebalanced the M1/M2 macrophage populations. This suggests a profound capacity for the treatment to retrain the host’s immune system, potentially enabling it to mount an effective anti-cancer response even at later stages of the disease. Dr. Hsu highlighted the clinical significance of this finding, noting that activating the immune system in such a targeted manner, without the systemic toxicities associated with direct interferon-gamma administration, is particularly meaningful for a difficult-to-treat cancer like TNBC, where many existing therapies carry severe side effects.
Beyond macrophages, the SFRP2 antibody also demonstrated the ability to rejuvenate the activity of T-cells, another critical component of the adaptive immune response. In many cancers, including TNBC, T-cells within the tumor microenvironment often become "exhausted," losing their ability to effectively recognize and eliminate cancer cells. Post-antibody treatment, neighboring T-cells exhibited increased activation and functionality. This revitalization of T-cell activity implies that the therapy could bolster weakened immune defenses, potentially improving the responsiveness to existing immunotherapies and opening avenues for synergistic treatment combinations.
The antibody’s efficacy extended to limiting metastatic spread, a primary cause of mortality in advanced cancer. In two distinct preclinical models of advanced TNBC, mice receiving the SFRP2 antibody developed significantly fewer lung tumors compared to untreated control groups. The presence of lung metastases is a stark indicator that cancer cells have entered the bloodstream and signals a considerably worse prognosis for patients. The observed reduction in metastatic burden underscores the antibody’s potential to significantly improve patient outcomes by disrupting a critical pathway for systemic disease progression.
Crucially, the effectiveness of the SFRP2 antibody was coupled with a high degree of targeting precision. When researchers tracked the antibody’s distribution within the body, they found it accumulated preferentially in tumor tissues, exhibiting minimal presence in healthy organs or normal cells. This selective targeting mechanism is a hallmark of advanced precision medicine, contrasting sharply with traditional chemotherapies that distribute broadly throughout the body, often leading to widespread collateral damage and severe systemic side effects. The localized action of the SFRP2 antibody suggests a potentially more favorable safety profile, enhancing its clinical viability.
One of the most profound findings of the study was the antibody’s capacity to overcome chemotherapy resistance, a major hurdle in long-term cancer management. Doxorubicin, a widely used chemotherapeutic agent for TNBC, frequently loses its efficacy over time as tumor cells adapt and develop resistance mechanisms. In experiments designed to mimic this clinical scenario, researchers generated cancer cell lines that no longer responded to doxorubicin. Remarkably, the SFRP2 antibody retained its ability to induce substantial cancer cell death in these resistant cells. Dr. Klauber-DeMore described this as a "very encouraging finding," as it suggests the therapy could remain effective even when standard treatment options have failed, offering a lifeline for patients with relapsed or refractory disease.
The comprehensive nature of the study highlights SFRP2’s pervasive presence throughout the tumor microenvironment, encompassing both malignant cells and critical immune components like tumor-infiltrating lymphocytes and tumor-associated macrophages. This widespread distribution makes SFRP2 an attractive therapeutic target, allowing for a simultaneous assault on multiple cancer vulnerabilities: tumor growth, immune evasion, and drug resistance. Furthermore, the observation that SFRP2 did not accumulate in healthy blood or immune cells reinforces the antibody’s potential for a favorable safety profile, differentiating it from certain other immune-based therapies that can induce systemic inflammation.
By establishing SFRP2 as a central nexus linking tumor proliferation, immune suppression, and therapeutic resistance, this research paves the way for a new class of precision therapies. Such an approach could not only stand alone as a potent treatment but also complement or synergize with existing immunotherapies for TNBC, potentially amplifying their effectiveness. Dr. Klauber-DeMore expressed profound optimism, articulating the hope that this therapeutic avenue will one day provide patients with a new option—one that not only aggressively targets the cancer but also fundamentally re-engineers the body’s innate immune capabilities to combat the disease.
While further rigorous investigation is essential, these preliminary results are exceptionally encouraging. The intellectual property surrounding the SFRP2 antibody has been licensed to Innova Therapeutics, a Charleston-based biotechnology firm co-founded by Dr. Klauber-DeMore. The company is actively pursuing funding to advance the therapy into its first-in-human clinical trials. The antibody has also garnered Rare Pediatric Disease and Orphan Disease designations from the U.S. Food and Drug Administration (FDA) for osteosarcoma, another malignancy strongly associated with SFRP2. These designations, while not permitting immediate patient use, provide crucial incentives and support for the continued development of therapies for rare and underserved conditions. Dr. Hsu reflected on the gratifying experience of contributing to research that holds such profound potential to impact the lives of countless patients in the future.
About the Author
